Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

IGC Pharma, Inc. Common Stock (NY:IGC)

0.2804 UNCHANGED
Streaming Delayed Price Updated: 8:00 PM EDT, Jun 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about IGC Pharma, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
IGC Pharma Advances In Alzheimer's Research From Pre-clinical Studies To Phase Two Trial With Its Novel Therapy Candidate IGC-AD1
--News Direct-- 
Via News Direct
InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Names Healthcare Leader to Board of Directors
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline
From IGC Pharma, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Reports ‘Promising’ Results in Preclinical Studies Evaluating Drug Candidate for Alzheimer’s Treatment
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model
From IGC Pharma, Inc.
Via Business Wire
InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Spotlighted in Ascendiant Equity Analyst Report
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target
From IGC Pharma, Inc.
Via Business Wire
InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Releases Q3 2024 Financial Results, Reports Corporate Achievements
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
IGC Pharma Announces Q3 2024 Earnings: Strategic Patent Achievements Propel Forward Amid Losses ↗
IGC Pharma's Q3 2024 results: Navigating financial dips with strategic patents in pain treatment and Alzheimer's therapy. 
Via Benzinga
Topics Intellectual Property
News headline image
IGC Pharma Reports Third Quarter Fiscal 2024 Results
From IGC Pharma, Inc.
Via Business Wire
InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Reports Data from Preclinical Studies Indicating Proprietary Drug Candidate Reduces Agitation in Alzheimer’s Mouse Model
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model
From IGC Pharma, Inc.
Via Business Wire
InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Reports Data Showing Proprietary Drug Candidate TGR-63 Reduces Plaque in Alzheimer’s
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Why IGC Pharma Stock Is Moving Higher ↗
IGC Pharma highlighted data from a trial in which the group treated with TGR-63 showed a 78% and 85% reduction in the cortical and hippocampal amyloid load, respectively, reaffirming its potential to... 
Via Benzinga
News headline image
IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer’s
From IGC Pharma, Inc.
Via Business Wire
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Activates ClinCloud in Phase 2b Alzheimer’s Trial
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer’s Trial
From IGC Pharma, Inc.
Via Business Wire
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Receives ‘Milestone’ Patent for Drug Formulation Used to Treat Agitation in Alzheimer’s
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer’s
From IGC Pharma, Inc.
Via Business Wire
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) to Participate at Biotech Showcase and BioPartnering @ JPM
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024
From IGC Pharma, Inc.
Via Business Wire
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Partners with Prominent Center to Integrate AI into Clinical Trials
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
IGC Pharma Announces Collaboration to Integrate AI into Clinical Trials
From IGC Pharma, Inc.
Via Business Wire
News headline image
AI And THC: IGC Pharma Teams Up With Colombian University For Alzheimer's Treatment Research ↗
IGC Pharma partners with University of Los Andes, to leverage AI for improving Alzheimer's disease treatment and clinical trial efficiency. 
Via Benzinga
Topics Artificial Intelligence
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Enters Strategic Collaboration to Advance AI Initiatives
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
IGC Pharma Announces Master Agreement with Leading South American University to Advance AI Initiatives
From IGC Pharma, Inc.
Via Business Wire
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Releases Q2 2024 Financial, Corporate Report
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
IGC Pharma Reports Second Quarter Fiscal 2024 Results
From IGC Pharma, Inc.
Via Business Wire
News headline image
Cannabis Based Pain Relief Solution Receives European Patent Approval ↗
IGC Pharma, Inc. (NYSE American: IGC) has been granted European Patent No. 3193862 by the European Patent Office for its innovative "Cannabinoid Composition and Method for Treating Pain." 
Via Benzinga
Topics Cannabis Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.